Denali Therapeutics Inc. $DNLI Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its position in Denali Therapeutics Inc. (NASDAQ:DNLI) by 28.7% during the 2nd quarter, Holdings Channel.com reports. The firm owned 3,161,972 shares of the company’s stock after selling 1,270,342 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Denali Therapeutics were worth $81,326,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in the business. Empowered Funds LLC bought a new stake in shares of Denali Therapeutics during the second quarter valued at about $371,000. Jefferies Financial Group Inc. acquired a new stake in Denali Therapeutics during the second quarter valued at approximately $885,000. Capstone Investment Advisors LLC acquired a new stake in shares of Denali Therapeutics during the 2nd quarter valued at $539,000. Bank of America Corp DE purchased a new stake in shares of Denali Therapeutics during the second quarter valued at $31,660,000. Finally, Odyssean LLC acquired a new position in shares of Denali Therapeutics in the 2nd quarter valued at $3,217,000. Institutional investors own 92.92% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on DNLI shares. Wall Street Zen raised Denali Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Sanford C. Bernstein reiterated a “hold” rating on shares of Denali Therapeutics in a report on Monday, June 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Denali Therapeutics in a research report on Friday, July 17th. Deutsche Bank Aktiengesellschaft boosted their price target on shares of Denali Therapeutics from $31.00 to $35.00 and gave the company a “buy” rating in a report on Thursday, July 16th. Finally, B. Riley Financial upped their price target on shares of Denali Therapeutics from $30.00 to $35.00 and gave the company a “buy” rating in a research report on Tuesday, August 25th. Fourteen analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Denali Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $35.85.

Insider Buying and Selling at Denali Therapeutics

In other news, insider Alexander O. Schuth sold 2,857 shares of the stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $25.07, for a total value of $71,624.99. Following the completion of the sale, the insider directly owned 281,763 shares of the company’s stock, valued at $7,063,798.41. This represents a 1.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 9.70% of the stock is owned by corporate insiders.

Denali Therapeutics Stock Down 1.8%

NASDAQ:DNLI opened at $22.85 on Thursday. The firm has a market capitalization of $3.65 billion, a price-to-earnings ratio of -8.05 and a beta of 1.01. Denali Therapeutics Inc. has a 1-year low of $12.58 and a 1-year high of $27.30. The company has a current ratio of 8.37, a quick ratio of 8.32 and a debt-to-equity ratio of 0.01. The business’s fifty day moving average price is $24.54 and its 200 day moving average price is $21.80.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.17). The company had revenue of $3.60 million during the quarter, compared to analysts’ expectations of $2.15 million. During the same period in the prior year, the company posted ($0.72) earnings per share. On average, sell-side analysts forecast that Denali Therapeutics Inc. will post -2.67 earnings per share for the current fiscal year.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.